NHP iPSC cardiomyocytes for translational cardiac safety

This poster presents Ncardia’s non-human primate (NHP) iPSC-derived ventricular cardiomyocyte platform, developed to help bridge in vivo NHP studies and human in vitro cardiac data and support translational interpretation of cardiac safety findings.

Download it now for a closer look at:

• How NHP iPSC-derived cardiomyocytes can be manufactured at large scale while maintaining high purity, ventricular identity and stable functional performance
  
• Acute MEA data showing electrophysiological responses to reference compounds including quinidine, moxifloxacin, BayK8644, dofetilide and nifedipine
• How sub-chronic exposure to sunitinib, doxorubicin and pentamidine reveals concentration- and time-dependent changes in field potential duration and beat rate
• How the model captures both acute ion-channel effects and delayed cardiac liabilities, including trafficking-mediated proarrhythmic responses

• How NHP iPSC-derived cardiomyocytes can support the interpretation of species-related differences between preclinical in vivo studies and human in vitro findings